medigraphic.com
ISSN 0016-3813 (Print)

2004, Number 2

<< Back Next >>

Gac Med Mex 2004; 140 (2)

The Quality of Life of the Asthmatic Child Caregiver.

Sienra-Monge JJL, del Río-Navarro BE, Álvarez-Amador M, Blandon-Vijil V, Gómez CR

Language: Spanish
References: 28
Page: 139-146
PDF size: 569.30 Kb.


ABSTRACT

Despite better understanding of the pathophysiology of asthma, the application of better drugs (potent anti-inflammatory medications and beta2 adrenergics with long-lasting effects), some symptoms persist and the illness itself, at the same time with exacerbation, may compromise the integrity of the patient. This calls for an evaluation of the impact of the ailment in different aspects of daily life of patients and of his/her caregivers. To address these situations, quality-of-life questionnaires for patients and caregivers were designed. With this study, our objective was to make up a quality-of-life questionnaire to be filled out by caregivers of asthmatic children treated with one of two therapeutic schemes: with inhaled steroids (EI), or the EI plus prolonged action bronchodilator (BAP). Materials and methods: controlled, experimental, and comparative clinical trial polling asthmatic child caregivers, applying a questionnaire designed by Elizabeth Juniper (PACQLQ). Patients and caregivers were randomized in two groups: group A was treated with IE (Beclomethasone) plus BAP (Salmeterol) during a 6-week period, followed by a 2-week wash-out period followed by a 6-week period with only IE. Group B were treated only with EI followed by a 2-week period of wash-out and a sixweek period with IE plus BAP. Caregivers filled in the questionnaires at the beginning, and at second, fourth, and sixth-weeks of treatment. Results: we included 30 patients and their caregivers who were randomized in two groups. Values in every group showed significant improvement in quality of life, as compared to basal values. Values between groups showed greater improvement in groups who received El plus BAP at the beginning. Conclusions: our study shows that administering treatment for asthma improves significantly the caregiver’s appreciation of quality of life with respect to the PACQLQ questionnaire. The group that received El therapy plus BAP at the beginning showed greater improvement. These results coincide with those published to date. We recommend the use of questionnaires at the beginning of the treatment as part of the integral evaluation of every patient with asthma.


REFERENCES

  1. National Institute of Health. National Heart, Lung and Blood Institute. Global strategy for asthma management and prevention. Ch. 5. Revised 2002. p. 75.

  2. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology. Practice parameters for the diagnosis and treatment of asthma. VI. Asthma management. J Allergy Clin Immunol 1995;96:749-820.

  3. Schwarts RH. Pediatric asthma, allergy & immunology. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. Pharmacologic therapy: the medications, Am Acad Asthma Allergy Clin Immunol 1997;11:59-71.

  4. Moore RH. Khan A. Dickey BF. Long-acting inhaled beta 2-agonists in asthma therapy. Chest 1998;113(4):1095-108.

  5. Schwarts RH. Pediatric asthma allergy & immunology. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. Pharmacologic therapy: managing asthma long term. Am Acad Asthma Allergy Clin Immunol 1997;11:81-104.

  6. Juniper EF. How important is quality of life in pediatric asthma? Pediatr Pulmonol 1997;(Suppl)15:17-21.

  7. Schipper H, Clinch J, Powell V. Definitions and conceptual issues. In: Spilker B, editor. Quality of life assesment in clinical trials. New York: Raven Press; 1990. p. 11-24.

  8. National Heart Lung and Blood Institute National Asthma Education and Prevention Program. Expert Panel Report 2. Guidelines for the diagnosis and managemente of asthma, National Institute of Health Pub No. 97-4051 Bethesda, MD, USA,1997.

  9. Sienra-Monge JJI, Baeza-Bacab MA. Parámetros prácticos para el diagnóstico y tratamiento del niño asmático. 1er ed. Academia Mexicana de Pediatria, México: Intersistemas; 1997. p. 9-46.

  10. Ortega-Cisneros M, Ramos-García B, Espinola-Reyna G, Sienra-Monge JJL. Pruebas de función pulmonar en pediatría. Bol Med Hosp Infant Mex 1997:54;47-53.

  11. Woolcock A. Lundback B. Ringdal N. Jacques LA. Comparison of addition of salmetrol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respi Crit Care Med 1996;153:1481-1488.

  12. Wilson MM. The association of asthma and obesity. Arch Inter Med 1999;159:2513-2514.

  13. Velarde E, Avila C. Evaluación de la calidad de vida. Salud Publica Mex 2002;44:349-361.

  14. Guyatt GH, Krinshner B, Jaeschke J. Measuring health status: what are the necessary measurement properties? J Clin Epidemiol 1992;45:1341-1345.

  15. Juniper FF,Guyatt EF, Willan A, Griffith LE. Determine a minimal important change in a disease-specific quality of life instrument. J Clin Epidemiol 1994;47:81-87.

  16. Juniper EF. How important is quality of life in pediatric asthma? Pediatr Pulmonol 1997;S15:17-21.

  17. Guyatt GH, Juniper EF, Feeny DH, Griffith LE, Ferrie PJ. Children and adult perceptions of childhood asthma. Pediatrics 1997;99(2):165-168.

  18. Townsend M, Feeney DH, Guyatt GH, Futlong WJ. Evaluation of the burden of illness for pediatric asthmatic patients and their parents. Ann Allergy 1991;67:403-408.

  19. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Resp Dis 1993;147:832-838.

  20. Juniper E. Minimum skills required by children to complete health-related quality of life instrument for asthma: comparison of measurement properties. Eur Resp J 1997;10:2285-2294.

  21. Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new health related quality of life instrument In: Spinker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2rd ed. New York: Raven Press, Ltd.; 1995. p. 49-56.

  22. Rutten-van Molken MP, Clusters F. Comparison of performance of four instruments in evaluting the effects of salmeterol on asthma quality of life. Eur Resp J 1995;8:888-898.

  23. Juniper EF, Guyatt, GH, Feeny PJ, Ferrie LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res 1996;5:35-46.

  24. Juniper EF, Guyatt, GH, Feeny PJ, Ferrie LE, Townsend M. Measuring quality of life in the parents of children with asthma. Qual Life Res 1996;5:27-34.

  25. Kemp J, Cook D. Salmeterol improves quality of life in patients with asthma requiring inhalated corticosteroids. Allergy Clin Immunol 1998;101:188-95.

  26. The British Guideline on Asthma Management, 1995. Review and position statement. Thorax 1997;52(Suppl 1):Sl-S2l.

  27. Warner JO, Naspitz CK. Third International Pediatric Consensus Statement on Management of Childhood Asthma. Pediatr Pulmonol 1998;25:1-17.

  28. Fish JE, Peters SP. Airway remodeling and persistent airway obstrucction in asthma. J Allergy Clin Immunol 1999; 104:509-516.




2020     |     www.medigraphic.com